Provigil (Modafinil) Cost in Texas 2026: Insurance, Medicaid, and Savings Options

Provigil, manufactured by Cephalon (now owned by Teva), is the brand name for modafinil, a prescription wakefulness promoter classified as a Schedule IV controlled substance. Patients take modafinil orally in tablet form. Though chemically related to armodafinil (Nuvigil), modafinil is a distinct molecule, and switching between the two requires a prescriber's approval.

Generic modafinil is almost always far cheaper than brand-name Provigil in Texas, because the patent protecting Provigil expired years ago and multiple generic manufacturers now compete on price. Exact dollar figures move by pharmacy, month, and discount program, so this article describes the pattern rather than locking in numbers that will go stale. Texas Medicaid coverage for modafinil is restrictive, telehealth prescribing is legal, and licensed compounding is available, each with real conditions attached.

Modafinil is FDA-approved for narcolepsy, as an add-on treatment for excessive sleepiness in obstructive sleep apnea, and for shift-work disorder, based on the original New Drug Application review (NDA 020717). Coverage, cash price, and telehealth rules are the parts of this page that change fastest and need to be checked against a current source before a patient acts on them; the approval history and drug class are the parts that do not change.

What is established versus what needs verification right now

Established and stable: Modafinil's FDA approval history and approved indications (narcolepsy, OSA adjunct, shift-work disorder), its Schedule IV controlled-substance status, and the general fact that generic modafinil costs substantially less than brand Provigil once generic competition exists. Plausible but requiring current confirmation: specific cash prices at named Texas pharmacy chains, specific commercial-insurer tier placement and copay amounts, and specific Texas Medicaid prior-authorization approval patterns, all of these shift with formulary updates, contract negotiations, and discount-card terms that are not visible from a general reference source. Not established here: any claim about a specific insurer's current denial rate, a specific dollar copay-card amount, or a projected number of Texas residents affected, those numbers were not sourced to a verifiable document and are removed rather than repeated.

Brand vs. generic pricing in Texas

Brand-name Provigil is priced by the manufacturer well above generic modafinil, consistent with the general pattern seen for most drugs once generic versions enter the market. Generic modafinil has been available since patent expiration and is now stocked at most major Texas retail chains (H-E-B, Walmart, CVS, Walgreens) and warehouse pharmacies.

Cash prices for a 30-day supply of generic modafinil 200 mg vary by pharmacy, region, and whether a discount card or coupon is applied at the counter. Readers should get a real-time quote from the filling pharmacy or a pharmacy price-comparison tool rather than relying on a number printed in an article, since pharmacy cash prices for generics can change month to month. The same caution applies to brand Provigil's list price, which is set by the manufacturer and can be adjusted at any time.

Modafinil's FDA approval, labeling, and approved indications are documented in the agency's NDA 020717 record, which is the primary source for what the drug is approved to treat and at what standard doses.

Texas Medicaid and modafinil coverage

Texas Medicaid's Preferred Drug List determines whether modafinil is covered, and PDLs are revised periodically, so any specific coverage statement is time-sensitive by nature. As of this review, modafinil coverage for Texas Medicaid beneficiaries generally requires prior authorization, and coverage for off-label uses (cognitive enhancement, fatigue unrelated to an FDA-approved sleep diagnosis) is not something a Medicaid formulary is likely to approve. Patients and prescribers should confirm current PDL status and prior-authorization criteria directly with Texas Medicaid or the patient's managed care organization before assuming a particular outcome.

Sleep disorders affecting daytime alertness are common in the general population, per CDC data, though narcolepsy specifically is a much smaller, rarer diagnosis than sleep disorders as a category. This article does not extrapolate a specific Texas patient count from national prevalence data, because that kind of calculation requires assumptions this page cannot verify.

A prescriber submitting a prior-authorization request for a Medicaid patient typically needs objective sleep-study documentation (polysomnography and/or Multiple Sleep Latency Test results) supporting the diagnosis. Whether that documentation results in approval depends on current program rules that a general reference page cannot promise.

Private insurance coverage for Provigil in Texas

Most commercial insurers treat generic modafinil as a formulary drug requiring prior authorization for at least one FDA-approved indication, and treat brand Provigil as a non-preferred or excluded product once a generic equivalent exists, this is a standard commercial formulary pattern for a drug with a long-available generic, not something specific to modafinil. Off-label prescribing (cognitive enhancement, non-approved fatigue indications) is far less likely to be approved by a commercial plan reviewer than one of the three FDA-approved uses.

Exact tier placement and copay amounts differ by insurer, plan design, and whether the plan is a marketplace plan or a self-insured employer plan. A specific number quoted for "typical copay" would be a guess dressed up as a fact; the reliable move is to check the plan's own formulary document or call member services before the first fill.

Compounded modafinil in Texas: legal status and access

Licensed 503A compounding pharmacies in Texas may compound modafinil for an individual patient against a valid prescription, consistent with FDA rules on human drug compounding, which require 503A pharmacies to compound in response to a specific patient prescription rather than producing batches for general distribution. The Texas State Board of Pharmacy licenses and inspects compounding facilities and enforces USP compounding standards, with authority to suspend or revoke a license for non-compliance.

Compounded modafinil is not the same regulatory product as FDA-approved generic modafinil. It has not gone through the ANDA bioequivalence pathway, so its absorption and effect cannot be assumed identical to the commercially approved tablet. A patient considering a compounded product should confirm the pharmacy's current Texas license status and ask what quality standards the specific batch was made under. Compounded pricing varies pharmacy to pharmacy and is not reliably cheaper or more expensive than commercial generic modafinil; it needs to be quoted directly.

Telehealth prescribing of modafinil in Texas

Modafinil is a Schedule IV controlled substance, and federal telemedicine flexibilities have, at various points since 2020, allowed initial prescribing of Schedule III through V controlled substances via a real-time audio-video visit without a prior in-person exam. These flexibilities have been extended through periodic rulemaking rather than made permanent, so their current status should be checked directly with the DEA or a current telehealth provider as of the date a patient is seeking care, not assumed from a past reading of the rule.

A Texas-licensed prescriber conducting a synchronous video visit and holding a valid DEA registration can generally prescribe modafinil to a Texas patient for an FDA-approved indication, and many telehealth platforms decline to prescribe it for off-label uses. Documentation from a prior sleep evaluation strengthens a telehealth prescribing decision for narcolepsy or shift-work disorder.

Ways patients try to reduce out-of-pocket modafinil cost

Common cost-reduction approaches reported by patients and pharmacies include: comparing cash prices across pharmacies using a discount card or price-comparison tool at the time of fill; asking a prescriber whether the FDA-scored 200 mg tablet is appropriate to split for a lower prescribed dose; this decision belongs to the prescriber, not a self-directed dose change; checking whether the manufacturer currently offers a copay assistance program for brand Provigil (these programs typically exclude government-insured patients and change their terms over time, so current terms need to be confirmed directly with the manufacturer); and asking whether a nearby federally qualified health center participates in the 340B Drug Pricing Program, which allows qualifying safety-net clinics to access discounted drug pricing for eligible patients.

None of these options guarantees a specific price, and eligibility rules for income-based assistance programs change. Treat any number quoted by a discount platform as a snapshot, not a guarantee, until confirmed at the pharmacy counter.

Dosing, safety, and monitoring considerations

Standard FDA-labeled dosing for narcolepsy and obstructive sleep apnea is 200 mg taken once in the morning; for shift-work disorder, the label describes dosing taken before the start of the work shift. Patients with hepatic impairment are generally started at a lower dose per labeling. Exact dosing for an individual patient is a decision for the prescribing clinician, not something this article can specify.

Modafinil's label describes common adverse effects including headache, nausea, and nervousness, and describes rare but serious skin reactions. Readers should review the current FDA label or ask their prescriber or pharmacist for the specific warnings that apply, rather than relying on percentage figures quoted secondhand, since the exact pooled trial numbers require direct verification against the primary FDA review documents.

Modafinil induces CYP3A4 and can reduce the effectiveness of hormonal contraceptives (pills, patches, rings) according to FDA labeling; an alternative or additional non-hormonal contraceptive method is generally recommended during modafinil therapy and for a period after stopping it, and this should be confirmed with a prescriber for the individual's contraceptive method. Modafinil also has clinically relevant interactions with other CYP3A4-affected drugs, including some immunosuppressants and antivirals, which a prescriber should screen for before starting therapy.

Modafinil does not require routine blood monitoring, but periodic reassessment of the underlying sleep disorder helps confirm the medication is still appropriate. Anyone who develops a new rash, mouth sores, fever with a skin reaction, new or worsening mood changes, or chest pain while taking modafinil should seek urgent medical evaluation rather than waiting for a routine follow-up.

Texas-specific regulatory notes

Texas classifies modafinil as a Schedule IV controlled substance, matching federal scheduling, and dispensing is tracked through the state's prescription monitoring program. Federal rules for Schedule III through V controlled substances generally allow up to five refills within six months from the date of issue, after which a new prescription is required; Texas does not add additional state-specific quantity limits beyond what federal law and individual insurers or pharmacy benefit managers impose. Prescribers and pharmacists are the accurate source for how these rules apply to a specific prescription.

Verification checklist: what to confirm before relying on a cost or coverage claim

This checklist separates facts that are stable enough to trust from a general reference page from facts that must be re-verified at the time of use, because they change on a schedule this page cannot track.

Stable, generally safe to treat as background fact:

• Modafinil's FDA-approved indications (narcolepsy, OSA adjunct, shift-work disorder) and its Schedule IV controlled-substance status
• The existence of a long-available generic version following patent expiration
• The general pattern that generics cost less than brand once generic competition exists
• Modafinil's known CYP3A4 interaction with hormonal contraceptives, as described in FDA labeling

Date-sensitive, verify directly before acting, and note the date checked:

• Current generic modafinil cash price at your specific pharmacy, with and without a discount card
• Current brand Provigil list price and whether a manufacturer copay card is active and what it currently excludes
• Your specific Texas Medicaid MCO's current PDL status and prior-authorization criteria for modafinil
• Your specific commercial plan's current formulary tier, copay, and prior-authorization requirement for modafinil
• Whether the federal telemedicine flexibility allowing controlled-substance prescribing without a prior in-person exam is still in effect at the time of the visit
• The compounding pharmacy's current Texas State Board of Pharmacy license status, if considering a compounded product
• Whether a nearby FQHC currently participates in 340B pricing and whether you meet its eligibility criteria

If a source (insurer portal, pharmacy quote, Medicaid MCO representative, licensed pharmacist) gives you a number that conflicts with anything above, trust the direct source over this article, and treat any number here as illustrative rather than current.